Medtronic PLC $MDT Shares Acquired by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC lifted its position in shares of Medtronic PLC (NYSE:MDT) by 0.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,744 shares of the medical technology company’s stock after buying an additional 340 shares during the quarter. Medtronic makes up about 2.5% of Murphy Pohlad Asset Management LLC’s holdings, making the stock its 6th largest position. Murphy Pohlad Asset Management LLC’s holdings in Medtronic were worth $5,818,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the last quarter. Clear Creek Financial Management LLC raised its stake in Medtronic by 26.1% in the 1st quarter. Clear Creek Financial Management LLC now owns 4,535 shares of the medical technology company’s stock valued at $408,000 after purchasing an additional 940 shares during the last quarter. Rossby Financial LCC acquired a new position in Medtronic in the 1st quarter valued at about $160,000. Keybank National Association OH raised its stake in Medtronic by 1.7% in the 1st quarter. Keybank National Association OH now owns 135,610 shares of the medical technology company’s stock valued at $12,186,000 after purchasing an additional 2,316 shares during the last quarter. Finally, Aaron Wealth Advisors LLC raised its stake in Medtronic by 12.6% in the 1st quarter. Aaron Wealth Advisors LLC now owns 7,743 shares of the medical technology company’s stock valued at $696,000 after purchasing an additional 865 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. UBS Group boosted their target price on shares of Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. Evercore ISI upped their price objective on shares of Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Mizuho upped their price objective on shares of Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Wells Fargo & Company upped their price objective on shares of Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, August 20th. Finally, Daiwa Capital Markets upped their price objective on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $102.82.

Insider Transactions at Medtronic

In other news, Director William R. Jellison bought 2,500 shares of the firm’s stock in a transaction dated Monday, August 25th. The stock was acquired at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. The trade was a 19.46% decrease in their position. The SEC filing for this sale provides additional information. 0.26% of the stock is currently owned by insiders.

Medtronic Stock Down 0.9%

Shares of NYSE:MDT opened at $90.88 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The stock has a market capitalization of $116.57 billion, a P/E ratio of 25.04, a PEG ratio of 2.42 and a beta of 0.78. The stock has a 50-day simple moving average of $94.38 and a 200-day simple moving average of $89.62.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter in the previous year, the business earned $1.23 EPS. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 17th. Stockholders of record on Friday, September 26th were issued a dividend of $0.71 per share. The ex-dividend date was Friday, September 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s payout ratio is presently 78.24%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.